Context Therapeutics: Delivering treatments in the female oncology space

Healthcare

Context Therapeutics: Delivering treatments in the female oncology space

United in its passion for helping women with cancer and specializing in the development of potentially first-in-class medicines, Context Therapeutics has embarked on a mission to develop treatments for patients with hormone-driven cancers.

In August 2022, Context announced a clinical trial collaboration and supply agreement with the Menarini Group to evaluate ONA-XR in combination with Menarini’s oral selective estrogen receptor degrader, elacestrant.

In this video, Context Therapeutics’ CEO and Co-founder, Martin Lehr, and Menarini Group CEO, Elcin Barker Ergun, discuss the collaboration.

For more information, visit Edison’s profile page for Context Therapeutics and see the latest update.

Want to receive content on Context Therapeutics? Complete the form below.

Latest

insight

Compressed matters #2

insight

March insight: Monetary risks ease

insight

Inside the mind of investors

insight

Compressed matters #1

Healthcare

October 2022 edition of Edison Healthcare Insight

Continue Reading
edison healthcare insight

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free